Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients (original) (raw)
Pathophysiology| December 01 2005
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
2Department of Radiology, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
2Department of Radiology, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
Search for other works by this author on:
Address correspondence and reprint requests to Giovanni Targher, MD, Division of Internal Medicine and Diabetes Unit, Ospedale “Sacro Cuore –don G. Calabria,” Via Sempreboni, 5, 37024 Negrar (VR), Italy. E-mail: [email protected]
Diabetes 2005;54(12):3541–3546
Nonalcoholic fatty liver disease (NAFLD) is closely correlated to several metabolic syndrome features. We assessed prospectively whether NAFLD predicts future cardiovascular disease (CVD) events among type 2 diabetic individuals, independent of metabolic syndrome features and other classical risk factors. We carried out a prospective nested case-control study in 2,103 type 2 diabetic patients who were free of diagnosed CVD at baseline. During 5 years of follow-up, 248 participants (case subjects) subsequently developed nonfatal coronary heart disease (myocardial infarction and coronary revascularization procedures), ischemic stroke, or cardiovascular death. Using risk-set sampling, 496 patients (control subjects) among those who remained free of diagnosed CVD during follow-up were randomly selected in a 2:1 ratio, matched for age and sex to the case subjects. After adjustment for age, sex, smoking history, diabetes duration, HbA1c, LDL cholesterol, liver enzymes, and use of medications, the presence of NAFLD was significantly associated with an increased CVD risk (odds ratio 1.84, 95% CI 1.4–2.1, P < 0.001). Additional adjustment for the metabolic syndrome (as defined by National Cholesterol Education Program Adult Treatment Panel III criteria) appreciably attenuated, but did not abolish, this association (1.53, 1.1–1.7, P = 0.02). In conclusion, NAFLD is significantly associated with a moderately increased CVD risk among type 2 diabetic individuals. This relationship is independent of classical risk factors and is only partly explained by occurrence of metabolic syndrome.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
You do not currently have access to this content.
Sign in
Pay-Per-View Access
$40.00